Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q1

4483.TEDINET S100RPCP
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥6.7bn2023-04-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥27.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥5.8bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Operating income¥2.5bn2023-04-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Profit before tax¥2.6bn2023-04-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥5.9bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.1bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥2.0bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥765m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥2.0bn2023-04-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥759m2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Total assets¥97.5bnat 2023-06-30Cons.Assets IFRS
Total assets¥98.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥63.3bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥31.7bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥34.0bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥65.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥64.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥31.4bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥65.9bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥64.5bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.4bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥23.0bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥22.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥10.1bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥1.4bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥4.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.1bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.5bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥3.2bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥273m2023-04-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥28.3bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥909m2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥32.422023-04-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥71.172022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥13.552022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥31.072023-04-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥67.692022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥12.732022-04-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio67.5%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio65.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio49.7%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥76m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥76m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥151m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-04-01 → 2023-06-30¥969m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-04-01 → 2023-06-30¥919m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥50m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-04-01 → 2023-06-30¥87m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue2023-04-01 → 2023-06-30¥4.5bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-04-01 → 2023-06-30¥4.5bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥25m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-04-01 → 2023-06-30¥1.3bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue2023-04-01 → 2023-06-30¥1.3bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue external2023-04-01 → 2023-06-30¥1.3bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentsegment profit2023-04-01 → 2023-06-30¥448m
—segment totalrevenue2023-04-01 → 2023-06-30¥6.8bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥6.7bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥76m
—segment totalsegment profit2023-04-01 → 2023-06-30¥1.8bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥58m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥58m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥90m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-06-30¥910m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-06-30¥869m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥41m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-06-30¥47m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-06-30¥3.7bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-06-30¥3.7bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥17m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-06-30¥1.1bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-06-30¥1.2bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-06-30¥1.2bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-06-30¥439m
—segment totalrevenue2022-04-01 → 2022-06-30¥5.8bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥5.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥58m
—segment totalsegment profit2022-04-01 → 2022-06-30¥1.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 632
ItemContextValueUnit
Other inv cf IFRSPrior1YTDDuration132000000JPY
Other inv cf IFRSCurrentYTDDuration37000000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-3245000000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-1465000000JPY
Proceeds from short term borrowings fin cf IFRSPrior1YTDDuration－JPY
Proceeds from short term borrowings fin cf IFRSCurrentYTDDuration1701000000JPY
Proceeds from long term borrowings fin cf IFRSPrior1YTDDuration－JPY
Proceeds from long term borrowings fin cf IFRSCurrentYTDDuration28000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-198000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-529000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-189000000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-223000000JPY
Proceeds from exercise of share acquisition rights fin cf IFRSPrior1YTDDuration41000000JPY
Proceeds from exercise of share acquisition rights fin cf IFRSCurrentYTDDuration48000000JPY
Dividends paid fin cf IFRSPrior1YTDDuration-563000000JPY
Dividends paid fin cf IFRSCurrentYTDDuration-751000000JPY
Other fin cf IFRSPrior1YTDDuration0JPY
Other fin cf IFRSCurrentYTDDuration-0JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-909000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration273000000JPY
Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRSPrior1YTDDuration-3065000000JPY
Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRSCurrentYTDDuration247000000JPY
Cash and cash equivalents IFRSPrior2YearInstant13192000000JPY
Cash and cash equivalents IFRSPrior1YearInstant22782000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration0JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration-0JPY
Cash and cash equivalents IFRSPrior1QuarterInstant10128000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant23029000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember3731000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember1175000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember869000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember5776000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration5776000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember17000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember41000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember58000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-58000000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember3749000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember1175000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember910000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember5835000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-58000000JPY
Revenue IFRSPrior1YTDDuration5776000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember1124000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember439000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember47000000JPY
Segment profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember1611000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass